186 publications
| Name | Date | Type | Actions |
|---|---|---|---|
SALES FOR 1ST QUARTER 2025 First-quarter sales of Essential products totaled 85 million euros, up+ 1.8% at constant exchange rates. |
Public releases | ||
Availability of the 2024 universal registration document On 24 April 2025, Vetoquinol filed its 2024 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2024 Annual results Annual sales: €539m (+2.2% at constant exchange rates) |
Public releases | ||
Annual sales 2024: €539 million Annual sales: €539 million (up 2.2% at constant exchange rates and up 1.9%. on a reported basis) |
Public releases | ||
Sales at end September 2024 At the end of September 2024, Vetoquinol sales totaled €398 million, up +1.6% on a reported basis and +1.8% at constant exchange rates. |
Public releases | ||
2024 half-year Results Sales: €264m (+3.2% as reported) |
Public releases | ||
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
Public releases | ||
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
Public releases | ||
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
Public releases |